FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications
FibroBiologics (NASDAQ: FBLG) has filed a patent application with the USPTO for methods of generating multipotent cells from fibroblasts found in donor tissue for clinical applications. The biotechnology company, which holds 275+ patents, focuses on developing therapeutics using fibroblasts and fibroblast-derived materials.
The innovation enables the generation of stable multipotent cells directly from donor-derived fibroblasts, which can differentiate into various cell types including chondrocytes, osteocytes, hepatocytes, and cardiomyocytes. According to Chief Scientific Officer Hamid Khoja, this method allows for obtaining larger quantities of stable and scalable multipotent cells, with enhanced ability to form 3D spheroid structures.
FibroBiologics (NASDAQ: FBLG) ha depositato una domanda di brevetto presso l'USPTO per metodi di generazione di cellule multipotenti a partire da fibroblasti presenti nei tessuti donatori, destinati ad applicazioni cliniche. Questa società biotecnologica, titolare di oltre 275 brevetti, si concentra sullo sviluppo di terapie basate su fibroblasti e materiali derivati da fibroblasti.
L'innovazione consente la produzione di cellule multipotenti stabili direttamente dai fibroblasti derivati dai donatori, capaci di differenziarsi in vari tipi cellulari come condrociti, osteociti, epatociti e cardiomiociti. Secondo il Chief Scientific Officer Hamid Khoja, questo metodo permette di ottenere quantità maggiori di cellule multipotenti stabili e scalabili, con una migliorata capacità di formare strutture sferoidali tridimensionali.
FibroBiologics (NASDAQ: FBLG) ha presentado una solicitud de patente ante la USPTO para métodos de generación de células multipotentes a partir de fibroblastos encontrados en tejidos donantes para aplicaciones clínicas. La compañía biotecnológica, que posee más de 275 patentes, se enfoca en desarrollar terapias utilizando fibroblastos y materiales derivados de fibroblastos.
La innovación permite la generación de células multipotentes estables directamente a partir de fibroblastos derivados de donantes, que pueden diferenciarse en varios tipos celulares como condrocitos, osteocitos, hepatocitos y cardiomiocitos. Según el Director Científico Hamid Khoja, este método posibilita obtener mayores cantidades de células multipotentes estables y escalables, con una capacidad mejorada para formar estructuras esferoidales en 3D.
FibroBiologics (NASDAQ: FBLG)는 임상 적용을 위해 기증자 조직에서 발견된 섬유아세포로부터 다능 세포를 생성하는 방법에 대한 특허 출원을 USPTO에 제출했습니다. 275개 이상의 특허를 보유한 이 생명공학 회사는 섬유아세포 및 섬유아세포 유래 소재를 이용한 치료제 개발에 주력하고 있습니다.
이 혁신 기술은 기증자 유래 섬유아세포로부터 직접 안정적인 다능 세포를 생성할 수 있게 하며, 이 세포들은 연골세포, 골세포, 간세포, 심근세포 등 다양한 세포 유형으로 분화할 수 있습니다. 최고과학책임자 Hamid Khoja에 따르면, 이 방법은 3D 구형체 구조를 형성하는 능력이 향상된, 안정적이고 확장 가능한 다능 세포를 더 많이 얻을 수 있게 합니다.
FibroBiologics (NASDAQ : FBLG) a déposé une demande de brevet auprès de l’USPTO pour des méthodes de génération de cellules multipotentes à partir de fibroblastes présents dans les tissus de donneurs, destinées à des applications cliniques. Cette entreprise biotechnologique, détentrice de plus de 275 brevets, se concentre sur le développement de thérapeutiques utilisant des fibroblastes et des matériaux dérivés de fibroblastes.
Cette innovation permet la production de cellules multipotentes stables directement issues de fibroblastes dérivés de donneurs, capables de se différencier en divers types cellulaires tels que chondrocytes, ostéocytes, hépatocytes et cardiomyocytes. Selon le directeur scientifique Hamid Khoja, cette méthode permet d’obtenir des quantités plus importantes de cellules multipotentes stables et évolutives, avec une capacité améliorée à former des structures sphéroïdes en 3D.
FibroBiologics (NASDAQ: FBLG) hat beim USPTO einen Patentantrag für Methoden zur Erzeugung multipotenter Zellen aus Fibroblasten in Spendergewebe für klinische Anwendungen eingereicht. Das Biotechnologieunternehmen, das über 275 Patente hält, konzentriert sich auf die Entwicklung von Therapeutika unter Verwendung von Fibroblasten und fibroblastabgeleiteten Materialien.
Die Innovation ermöglicht die Erzeugung von stabilen multipotenten Zellen direkt aus spenderabgeleiteten Fibroblasten, die sich in verschiedene Zelltypen wie Chondrozyten, Osteozyten, Hepatozyten und Kardiomyozyten differenzieren können. Laut Chief Scientific Officer Hamid Khoja erlaubt diese Methode die Gewinnung größerer Mengen stabiler und skalierbarer multipotenter Zellen mit verbesserter Fähigkeit zur Bildung von 3D-Sphäroidstrukturen.
- Patent filing strengthens intellectual property portfolio in regenerative medicine
- Technology enables larger quantities of stable and scalable multipotent cells
- Enhanced ability to form 3D spheroid structures expands therapeutic potential
- Method addresses long-standing challenges in scalable regenerative treatments
- Early-stage technology with no proven clinical success yet
- Significant R&D and clinical validation still required
- Company faces liquidity and capital resource challenges
- Unpredictable relationship between preclinical and clinical results
Insights
FibroBiologics' new patent filing for multipotent cell generation from donor tissue strengthens their IP portfolio and expands therapeutic potential.
FibroBiologics has filed a new patent application covering methods to generate multipotent cells from donor tissue fibroblasts, adding to their extensive portfolio of 275+ patents issued and pending. This development is significant for several reasons.
The technology addresses a crucial challenge in regenerative medicine - obtaining stable, scalable sources of multipotent cells. While stem cells typically dominate discussions about multipotency, this patent leverages fibroblasts' natural ability to differentiate into various cell types including chondrocytes, osteocytes, hepatocytes, and cardiomyocytes.
What makes this particularly valuable is the enhanced ability of these multipotent fibroblasts to form 3D spheroid structures, which could significantly advance both therapeutic applications and drug development platforms. The method appears to improve upon existing techniques by generating larger quantities of stable cells directly from donor-derived fibroblasts.
This patent application strategically extends FibroBiologics' intellectual property in the fibroblast space, potentially creating additional barriers to entry for competitors while opening new commercial avenues for the company. It aligns with their core focus on developing fibroblast and fibroblast-derived therapeutics for chronic diseases.
The technology could accelerate the company's development timeline across multiple therapeutic areas by providing a more efficient cell production method. However, as with all biotech innovations, significant scientific validation and clinical testing will be required to demonstrate the practical applications of this approach.
HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent and Trademark Office covering methods of generating multipotent cells from fibroblasts found in donor tissue for clinical applications.
Multipotency refers to a flexible cellular state in which a cell has the potential to differentiate into multiple specialized cell types, depending on the environmental conditions or stimuli it encounters. While stem cells have garnered the most attention on being multipotent, fibroblasts are also considered multipotent and can be directly differentiated into many cell types including chondrocytes, osteocytes, hepatocytes and cardiomyocytes. This patent application broadly relates to methods for generating multipotent cells directly from fibroblasts found in human donor tissues.
“This method provides us with the ability to obtain larger quantities of stable and easily scalable multipotent cells from donor-derived fibroblasts for use in clinical applications,” said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. “Multipotent fibroblasts also show enhanced ability to form 3D spheroid structures, further expanding their potential across a range of therapeutic and drug development areas.”
Pete O’Heeron, Founder and Chief Executive Officer of FibroBiologics, said, “By enabling the generation of stable, multipotent cells directly from donor tissue, this innovation addresses long-standing challenges in the field and opens new possibilities for scalable, regenerative treatments.”
For more information, please visit FibroBiologics’ website or email FibroBiologics at info@fibrobiologics.com.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential of multipotent fibroblasts across a range of therapeutic and drug development areas and new possibilities for scalable, regenerative treatments. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
What is the significance of FBLG's new patent application for multipotent cells?
How many patents does FibroBiologics (FBLG) currently have?
What cell types can FibroBiologics' multipotent fibroblasts differentiate into?
What are the main advantages of FBLG's new multipotent cell generation method?
What are the key risks facing FibroBiologics' (FBLG) technology development?
